Abstract

Fulminant myocarditis (FM) is a rare disease that may progress rapidly to refractory cardiogenic shock requiring temporary mechanical circulatory support. Venoarterial extracorporeal membrane oxygenation (VA-ECMO) has been used to provide biventricular support in these patients, however, studies have demonstrated conflicting results, likely due to small sample size. We conducted a systematic review and meta-analysis to evaluate short-term mortality after VA-ECMO in patients with FM. Seven relevant databases were systematically searched on June 1st, 2019 to identify studies evaluating death at 30 days and/or hospital discharge (short-term mortality) after VA-ECMO support for FM. We included studies with n≥5, published after 2009. Mortality risk was meta-analyzed using random effect models. We performed a meta-regression analysis to explore heterogeneity based on a priori defined factors. We assessed the quality of the evidence using the GRADE approach. We included 12 retrospective studies (Figure) with 859 patients, mean age 38 ± 12 years to 59 ± 17 years, proportion of female patients ranged from 40% to 60%. In 5 studies (n=144), FM was verified by biopsy. In 4 studies (n=67), the reported use of steroids ranged from 13% to 41%, and in 4 studies (n=207), co-therapy with IABP ranged from 65% to 96%. The pooled short-term mortality was 41% (95% CI 34-47%; I2=64%). The exploration of heterogeneity showed that age and sex significantly impacted short-term mortality after VA-ECMO with lowest mortality in studies with younger populations and higher proportion of female patients. In patients with rapidly progressive FM, short-term mortality was 41%. Mortality might be even lower in younger and in female patients. Cardiopulmonary support with VA-ECMO provides an invaluable tool in the treatment of fatal FM, where appropriate patient selection can further improve their outcomes.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call